List of Excipients in Branded Drug DIASTAT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	DIASTAT	diazepam	0187-0658	ALCOHOL
Bausch Health US LLC	DIASTAT	diazepam	0187-0658	BENZOIC ACID
Bausch Health US LLC	DIASTAT	diazepam	0187-0658	BENZYL ALCOHOL
Bausch Health US LLC	DIASTAT	diazepam	0187-0658	HYPROMELLOSE

Diastat Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

Diastat is a diazepam rectal gel for the acute treatment of seizure clusters in patients with epilepsy who require intermittent rescue therapy. Its commercial value is tied to rapid administration, caregiver usability, pediatric dosing flexibility, and the availability of a prefilled rectal delivery system. The core excipient opportunity is therefore not a simple reformulation of diazepam. It is the development of a better-tolerated, easier-to-administer, more stable, or more commercially efficient rescue product.

The main opportunities are intranasal or buccal delivery, lower-irritancy excipient systems, improved dose-conversion technology, pediatric-friendly packaging, and products designed for global markets where Diastat has limited availability.

What is Diastat and how does its formulation work?

Diastat contains diazepam in a rectal gel formulation. The product is supplied in prefilled delivery systems with dose strengths intended for individualized administration based on age, weight, and clinical response. The gel is administered rectally during a seizure cluster by a trained caregiver or patient when appropriate.

The formulation uses a nonaqueous or mixed-solvent vehicle to solubilize diazepam, a poorly water-soluble benzodiazepine. Public labeling identifies excipients including propylene glycol, alcohol, benzoic acid, sodium benzoate, and water. The exact inactive-ingredient presentation should be confirmed against the current FDA-approved label and product-specific regulatory filing before development or regulatory submission.[1]

Functional role of Diastat excipients

Excipient or excipient class	Likely formulation role	Commercial and technical relevance
Propylene glycol	Solvent and cosolvent for diazepam	Supports drug loading but may contribute to rectal irritation or tolerability concerns
Alcohol or ethanol	Cosolvent and possible antimicrobial-supporting component	Can improve solubilization but creates irritation, flammability, packaging, and pediatric-use considerations
Benzoic acid	Preservative and pH-modifying component	Helps microbiological control in an aqueous-containing system
Sodium benzoate	Preservative and buffering-related component	Supports product stability but requires attention to concentration, local tolerability, and pediatric exposure
Water	Vehicle component	Enables gel formation and affects solubility, stability, microbial control, and dose uniformity
Gel-forming system	Controls viscosity and retention	Influences leakage, caregiver handling, absorption, and device performance

The commercial performance of Diastat depends on the interaction between the formulation and the delivery system. Viscosity that is too low can increase leakage. Viscosity that is too high can delay administration or impair syringe delivery. Solvent composition affects drug solubility, mucosal tolerability, extractables and leachables, and container compatibility.

What excipient strategy is most relevant for a Diastat competitor?

The strongest strategy is a low-volume, rapidly dissolving, mucosa-compatible formulation combined with a delivery system that reduces caregiver steps. A direct generic copy of the existing rectal gel may face limited differentiation and may encounter device, formulation, bioequivalence, and market-adoption barriers.

Strategy 1: Reduce solvent-related irritation

A reformulated product could reduce reliance on ethanol, propylene glycol, or other aggressive cosolvents if diazepam solubility can be maintained through:

• pH optimization;
• alternative cosolvents;
• cyclodextrin complexation;
• lipid or self-emulsifying systems;
• polymeric solubilizers;
• microemulsion technology; or
• reduced drug concentration combined with a more efficient applicator.

The target would be a formulation with lower local irritation while preserving rapid drug release and adequate shelf life. Any reduction in organic solvent concentration must be evaluated against diazepam precipitation, crystallization during storage, syringe clogging, and dose nonuniformity.

Strategy 2: Improve rectal retention

A higher-viscosity or bioadhesive gel could reduce leakage and improve dose retention. Candidate excipient classes include:

• cellulose derivatives;
• carbomers;
• polycarbophil;
• poloxamers;
• chitosan derivatives; and
• other mucoadhesive polymers.

The main risk is that excessive viscosity may slow syringe discharge, increase administration force, or delay diazepam absorption. A commercially viable formulation would need to balance retention with rapid delivery through a small-bore applicator.

Strategy 3: Use a solvent-free or low-solvent platform

A solid-in-liquid suspension, lipid-based system, or polymeric dispersion could address concerns associated with alcohol and propylene glycol. These approaches may improve tolerability but introduce new risks:

• dose settling;
• redispersibility;
• sedimentation during storage;
• syringe orientation sensitivity;
• incomplete dose delivery;
• changes in absorption rate; and
• more complex manufacturing controls.

For an acute rescue product, the product must remain ready for use after prolonged storage in a home, school, vehicle, or emergency kit. A formulation that requires shaking, warming, or visual inspection would reduce caregiver reliability.

Strategy 4: Optimize pediatric exposure

Diastat is used in pediatric patients, making excipient exposure commercially important. Reformulation programs should assess cumulative exposure to propylene glycol, ethanol, preservatives, and other excipients in children who may receive repeated rescue doses.

The most valuable formulation claims may involve:

• reduced concentration of alcohol;
• reduced propylene glycol exposure;
• absence of potentially sensitizing preservatives;
• lower administered volume;
• improved local tolerability; and
• suitability for repeated intermittent use.

These claims would require clinical tolerability data and cannot be established solely through laboratory formulation work.

What formulations are protected by Diastat-related intellectual property?

The relevant intellectual-property categories include the diazepam gel composition, rectal delivery device, dose-selection mechanism, use in seizure clusters, and manufacturing or packaging methods.

Older Diastat composition and delivery patents are likely to have reached the end of their standard U.S. patent terms. The commercial question is therefore less likely to be whether a basic diazepam rectal gel concept remains broadly patentable and more likely to be whether a specific formulation or device improvement can support new patent claims.

Potential patentable claim areas

Claim area	Potential claim subject matter	Relative value
Excipient composition	Specific solvent, preservative, polymer, or pH range	Moderate if linked to measurable performance
Low-irritancy formulation	Reduced alcohol or propylene glycol with preserved bioavailability	High if supported by comparative clinical data
Bioadhesive gel	Polymer concentration and retention profile	Moderate to high
Delivery device	Applicator geometry, dose lock, depth limiter, or administration sequence	High if difficult to design around
Dose algorithm	Age- or weight-based dose selection and device coding	Moderate, subject to patent eligibility and prior art
Packaging	Stability-enhancing container closure and unit-dose presentation	Moderate
Manufacturing	Mixing, deaeration, filling, or crystallization-control process	Moderate if process produces a distinct product profile
Method of use	Rescue treatment for seizure clusters using a specified dose or regimen	Limited if broad prior art exists

A patent estate would be stronger if claims covered both the formulation and the device. A composition-only patent may be vulnerable to design-around strategies involving a different polymer, solvent ratio, preservative system, or delivery route.

When does Diastat lose exclusivity?

Diastat’s original market exclusivity and core patent protection are historical rather than prospective commercial barriers. The FDA-approved product has been marketed for many years, and the core rectal diazepam concept is mature. Current competitive analysis should focus on listed patents, regulatory exclusivity, device rights, trademarks, and product-specific data protections rather than assuming that basic diazepam protection remains active.

The Orange Book is the authoritative source for patents listed against an FDA-approved drug application. The relevant review should include:

1. current patents listed for the Diastat NDA;
2. patent use codes;
3. expiration dates;
4. pediatric exclusivity extensions;
5. any delisted patents;
6. litigation under the Hatch-Waxman framework; and
7. whether a proposed abbreviated new drug application would require a Paragraph IV certification.[2]

A generic applicant could face a Paragraph IV issue only if an unexpired, Orange Book-listed patent covers the reference product or an approved use. If no relevant unexpired patent remains listed, the principal barriers would shift to formulation development, device equivalence, regulatory classification, manufacturing capability, and market access.

What is the FDA regulatory status of Diastat?

Diastat is an FDA-approved prescription rescue product for seizure clusters associated with epilepsy. The product is regulated as a drug-device combination because the diazepam formulation is supplied in a prefilled rectal delivery system.

A follow-on applicant must determine whether the product can be pursued through an ANDA or whether formulation, device, or clinical differences would require a different pathway. Key regulatory issues include:

• pharmaceutical equivalence to the reference product;
• dosage-form equivalence;
• strength and dose-volume matching;
• inactive-ingredient justification;
• device compatibility;
• delivered-dose accuracy;
• in-use stability;
• microbial limits and preservative effectiveness;
• local tolerability;
• comparative pharmacokinetics; and
• demonstration that differences do not alter safety or effectiveness.

A materially different excipient system could increase regulatory risk if it changes absorption rate, rectal retention, systemic exposure, or local safety. A new route, such as intranasal administration, would generally be a new drug product rather than a conventional generic Diastat substitute.

Which companies compete with Diastat?

Diastat competes within the rescue-seizure market rather than only against rectal diazepam products. The main U.S. alternatives include Valtoco intranasal diazepam and Nayzilam intranasal midazolam.

Product	Active ingredient	Route	Sponsor or manufacturer	Commercial differentiation
Diastat	Diazepam	Rectal gel	Bausch Health-related commercial organization	Established product, weight-based dosing, rectal administration
Valtoco	Diazepam	Intranasal spray	Neurelis	Needle-free and rectal-free delivery; age- and dose-specific products
Nayzilam	Midazolam	Intranasal spray	UCB	Rapid intranasal administration with a different benzodiazepine
Generic rectal diazepam	Diazepam	Rectal gel or related dosage form	Multiple potential manufacturers	Price competition and pharmacy access

Intranasal products create pressure on Diastat because they reduce privacy concerns, caregiver resistance, and administration complexity. Their excipient strategies are also commercially relevant: nasal formulations require control of pH, osmolality, spray performance, preservative exposure, and nasal tolerability.

How does Diastat compare with intranasal rescue products?

Rectal administration remains clinically effective but can be difficult in public settings, schools, ambulances, and situations involving limited caregiver access. Intranasal delivery has a strong usability advantage, although it introduces its own formulation constraints.

Attribute	Diastat rectal gel	Intranasal diazepam	Intranasal midazolam
Administration privacy	Low	Higher	Higher
Caregiver training burden	Moderate	Lower in many settings	Lower in many settings
Mucosal exposure	Rectal	Nasal	Nasal
Formulation challenge	Solubilization, retention, dose delivery	Sprayability, nasal tolerability, absorption	Sprayability, pH, concentration, absorption
Pediatric positioning	Established	Strong commercial growth opportunity	Established rescue alternative
Device dependence	Prefilled rectal applicator	Nasal spray device	Nasal spray device
Differentiation opportunity	Better tolerability and retention	Better spray performance and comfort	Better tolerability and dose flexibility

The strongest commercial opportunity for a Diastat-related program may therefore be a new route rather than a direct rectal reformulation. A rectal product can still compete where intranasal delivery is unsuitable, unavailable, or not accepted by local treatment protocols.

What excipient opportunities exist in intranasal diazepam?

An intranasal diazepam product requires a high drug concentration because the nasal cavity accepts only a limited spray volume. Excipient selection must support rapid absorption without causing excessive nasal irritation or impaired mucociliary function.

Potential development areas include:

• solubilization with lower-irritancy cosolvents;
• cyclodextrin-based diazepam delivery;
• mucoadhesive polymers that do not materially delay absorption;
• isotonic or near-isotonic systems;
• pH adjustment for comfort and stability;
• preservative-free unit-dose packaging;
• spray plume optimization; and
• low-volume metered-dose delivery.

Commercially valuable claims could involve a defined spray volume, a specific diazepam concentration, reduced nasal deposition variability, or improved pharmacokinetic consistency across pediatric and adult populations.

What manufacturing and IP barriers affect a Diastat competitor?

The active pharmaceutical ingredient is generic and widely available. The more meaningful barriers are formulation reproducibility, device integration, filling accuracy, and regulatory evidence.

Manufacturing barriers

A commercial manufacturer must control:

• diazepam dissolution and homogeneity;
• solvent evaporation;
• gel viscosity;
• preservative concentration;
• microbial quality;
• syringe fill weight;
• applicator assembly;
• dose delivery at temperature extremes;
• container closure integrity; and
• long-term crystallization or precipitation.

Rectal rescue products may remain in household or emergency-kit conditions for years. Stability data must account for temperature cycling, freezing and thawing, light exposure, and mechanical stress during transport.

Device and packaging barriers

A prefilled applicator is part of the product’s clinical performance. The device must deliver the labeled dose even when used by a stressed caregiver with limited training. Useful improvements include:

• clearer dose identification;
• tamper-resistant dose settings;
• depth control;
• reduced administration force;
• improved lubrication;
• child-resistant packaging;
• integrated instructions; and
• better portability.

Device patents can provide stronger market protection than routine excipient patents if the design is difficult to replicate without infringing.

What licensing deals could create commercial opportunities?

Licensing opportunities exist in five areas:

1. Diazepam solubilization technology.
2. Mucoadhesive or controlled-retention excipients.
3. Intranasal delivery platforms.
4. Prefilled syringe and applicator technology.
5. Pediatric dose-selection and adherence systems.

A pharmaceutical company with an existing rescue-neurology franchise could license a reformulated rectal product to extend geographic coverage or serve patients unable to use intranasal products. A device company could license a next-generation applicator to a generic manufacturer. A specialty pharmaceutical company could acquire regional rights where Diastat access is limited and local seizure-rescue protocols favor rectal diazepam.

The most defensible deal structure would link royalties to regulatory approval and commercial milestones rather than grant broad rights to an unvalidated excipient platform.

What generic launch risks exist for Diastat?

A generic launch could proceed through several scenarios.

Scenario 1: Direct rectal-gel generic

This is the lowest differentiation strategy. It could compete on price but would need to match the reference product’s formulation, strength, dose volumes, device, labeling, and performance. The market may be constrained by limited prescription switching and caregiver preference for known devices.

Scenario 2: Improved rectal formulation

A lower-irritancy or lower-volume product could support premium pricing. It may require a new drug application or supplemental clinical evidence if the formulation differs materially from the reference product.

Scenario 3: Intranasal diazepam

This has the highest commercial upside but also the greatest development and regulatory burden. The product would compete directly with Valtoco and would need clear advantages in tolerability, dose flexibility, spray performance, cost, or geographic availability.

Scenario 4: Regional or institutional product

A manufacturer could target emergency departments, schools, long-term care, ambulance services, or international markets. Unit-dose packaging, storage robustness, and simple training could be more important than broad consumer branding.

How strong is the Diastat patent estate?

The core Diastat patent estate should be treated as mature. The strongest remaining barriers, if any, are likely to involve product-specific device claims, later improvements, trademarks, regulatory filings, manufacturing know-how, or patents associated with competing products rather than broad ownership of diazepam rectal rescue therapy.

Patent strength should be assessed using four tests:

Test	Strong position	Weak position
Claim scope	Covers formulation and delivery system	Covers a narrow excipient ratio
Design-around risk	Few practical alternatives	Many substitute excipients
Evidence	Comparative clinical or stability data	Only theoretical formulation advantages
Commercial relevance	Claim maps to a needed product attribute	Claim covers a feature with no market value

A new excipient patent is most valuable when it solves a measurable problem: lower irritation, faster absorption, less leakage, improved stability, or more reliable dose delivery.

Key Takeaways

• Diastat is a mature diazepam rectal-gel product whose commercial differentiation depends heavily on its delivery system.
• The primary excipient opportunities are lower-irritancy solvent systems, improved retention polymers, lower-volume gels, and pediatric exposure reduction.
• Direct generic competition is likely to be price-led and may have limited differentiation.
• Intranasal diazepam is the larger commercial opportunity but requires a new formulation, spray device, and regulatory strategy.
• The most valuable new patents would combine formulation and device claims.
• Manufacturing risks include diazepam precipitation, viscosity drift, dose nonuniformity, microbial control, and device compatibility.
• Orange Book review is required before making a definitive Paragraph IV or patent-expiration assessment.
• Competitive pressure comes principally from Valtoco and Nayzilam, not only from generic rectal diazepam.
• Licensing opportunities are strongest in intranasal delivery, applicator technology, solubilization, and pediatric rescue-use systems.

FAQs

Can propylene glycol be removed from Diastat?

Possibly, but removing propylene glycol may reduce diazepam solubility and create precipitation or dose-uniformity problems. A replacement system would require stability, delivery, tolerability, and bioavailability testing.

Is a Diastat formulation patent likely to support premium pricing?

Only if the patent protects a clinically meaningful improvement, such as reduced irritation, lower leakage, faster absorption, or more reliable administration. Narrow excipient-ratio claims generally provide weaker commercial protection.

Could a preservative-free rectal diazepam product compete with Diastat?

Yes, particularly in a single-use, hermetically sealed system. The product would still need adequate microbial control, container-closure integrity, stability, and manufacturing validation.

What is the largest unmet need in diazepam rescue delivery?

The main opportunity is a product that combines rapid absorption, low mucosal irritation, simple caregiver administration, stable storage, and flexible pediatric dosing without requiring complex preparation.

Does a new excipient automatically require a new FDA approval pathway?

No. The pathway depends on the extent of the formulation and device differences, whether pharmaceutical equivalence can be established, and whether the changes affect safety, efficacy, or product performance.

References

1. U.S. Food and Drug Administration. (n.d.). Diastat AcuDial and Diastat rectal gel prescribing information. FDA.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
3. DailyMed. (n.d.). Diastat diazepam rectal gel labeling. National Library of Medicine.
4. U.S. Food and Drug Administration. (n.d.). Valtoco diazepam nasal spray prescribing information. FDA.
5. U.S. Food and Drug Administration. (n.d.). Nayzilam midazolam nasal spray prescribing information. FDA.
6. U.S. Food and Drug Administration. (n.d.). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. FDA.